# Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

> **NCT04520451** · PHASE2 · COMPLETED · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 27 (actual)

## Conditions studied

- Immunoglobulin G4 Related Disease

## Interventions

- **DRUG:** rilzabrutinib
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT04520451
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-22
- **Primary completion:** 2024-10-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520451, "Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04520451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*